These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 30794062)

  • 1. Gut microbiota metabolizes nabumetone
    Jourova L; Anzenbacher P; Matuskova Z; Vecera R; Strojil J; Kolar M; Nobilis M; Hermanova P; Hudcovic T; Kozakova H; Kverka M; Anzenbacherova E
    Xenobiotica; 2019 Nov; 49(11):1296-1302. PubMed ID: 30794062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presence or absence of microbiome modulates the response of mice organism to administered drug nabumetone.
    Jourová L; Lišková B; Lněničková K; Zemanová N; Anzenbacher P; Hermanová P; Hudcovic T; Kozáková H; Anzenbacherová E
    Physiol Res; 2020 Dec; 69(Suppl 4):S583-S594. PubMed ID: 33646003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A metabolic pathway for the prodrug nabumetone to the pharmacologically active metabolite, 6-methoxy-2-naphthylacetic acid (6-MNA) by non-cytochrome P450 enzymes.
    Matsumoto K; Hasegawa T; Ohara K; Takei C; Kamei T; Koyanagi J; Takahashi T; Akimoto M
    Xenobiotica; 2020 Jul; 50(7):783-792. PubMed ID: 31855101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical power of LLE-HPLC-PDA-MS/MS in drug metabolism studies: identification of new nabumetone metabolites.
    Nobilis M; Mikušek J; Szotáková B; Jirásko R; Holčapek M; Chamseddin C; Jira T; Kučera R; Kuneš J; Pour M
    J Pharm Biomed Anal; 2013 Jun; 80():164-72. PubMed ID: 23584048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of human flavin-containing monooxygenase (FMO) 5 in the metabolism of nabumetone: Baeyer-Villiger oxidation in the activation of the intermediate metabolite, 3-hydroxy nabumetone, to the active metabolite, 6-methoxy-2-naphthylacetic acid
    Matsumoto K; Hasegawa T; Ohara K; Kamei T; Koyanagi J; Akimoto M
    Xenobiotica; 2021 Feb; 51(2):155-166. PubMed ID: 33146575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses.
    Soma LR; Uboh CE; Rudy JA; Smith MS
    Am J Vet Res; 1996 Apr; 57(4):517-21. PubMed ID: 8712517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extractionless determination of 6-methoxy-2-naphthylacetic acid, a major metabolite of nabumetone, in human plasma by high-performance liquid chromatography.
    de Jager AD; Hundt HK; Hundt AF; Swart KJ; Knight M; Roberts J
    J Chromatogr B Biomed Sci Appl; 2000 Apr; 740(2):247-51. PubMed ID: 10821411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients.
    Kendall MJ; Chellingsworth MC; Jubb R; Thawley AR; Undre NA; Kill DC
    Eur J Clin Pharmacol; 1989; 36(3):299-305. PubMed ID: 2744071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Determination of nabumetone and 6-methoxy-2-naphthylacetic acid in plasma using HPLC with UV and MS detection].
    Nespesná L; Stícha M; Matousková O; Perlík F; Slanar O
    Ceska Slov Farm; 2011 Feb; 60(1):17-24. PubMed ID: 21650014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel injection strategy of flurbiprofen axetil by inhibiting protein binding with 6-methoxy-2-naphthylacetic acid.
    Ogata K; Takamura N; Tokunaga J; Ikeda T; Setoguchi N; Tanda K; Yamasaki T; Nishio T; Kawai K
    Eur J Drug Metab Pharmacokinet; 2016 Apr; 41(2):179-86. PubMed ID: 25537338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nabumetone pharmacokinetics in patients with varying degrees of renal impairment.
    Boelaert JR; Jonnaert HA; Daneels RF; Schurgers ML; Thawley AR; Undre NA; Cooper DL
    Am J Med; 1987 Oct; 83(4B):107-9. PubMed ID: 3687998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penetration of the active metabolite of nabumetone into synovial fluid and adherent tissue of patients undergoing knee joint surgery.
    Miehlke RK; Schneider S; Sörgel F; Muth P; Henschke F; Giersch KH; Münzel P
    Drugs; 1990; 40 Suppl 5():57-61. PubMed ID: 2081495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nabumetone and 6-MNA Pharmacokinetics, Assessment of Intrasubject Variability and Gender Effect.
    Světlík S; Štícha M; Matoušková O; Nespěšná L; Sklenář Z; Bartůněk A; Perlík F; Slanař O
    Am J Ther; 2016; 23(6):e1498-e1503. PubMed ID: 25393072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [6-methoxy-2-naphthylacetic acid level in plasma, synovial fluid and adjacent tissue in patients with rheumatoid arthritis or gonarthroses after a 4-day therapy with nabumetone (Arthaxan)].
    Miehlke RK; Schneider S; Sörgel F; Muth P; Henschke F; Fedder M
    Z Rheumatol; 1991; 50(2):103-8. PubMed ID: 1872041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence study of nabumetone: tablet versus suspension.
    Daigneault EA; Ferslew KE; Stanton P
    Am J Med; 1987 Oct; 83(4B):11-4. PubMed ID: 3687999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using high-performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection.
    Nobilis M; Kopecký J; Kvetina J; Svoboda Z; Pour M; Kunes J; Holcapek M; Kolárová L
    J Pharm Biomed Anal; 2003 Aug; 32(4-5):641-56. PubMed ID: 12899954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in vitro effects of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone, on rat gastric mucosal eicosanoid synthesis and metabolism.
    Melarange R; Spangler R; Hoult JR
    Prostaglandins Leukot Essent Fatty Acids; 1996 Sep; 55(3):195-200. PubMed ID: 8931119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the antiinflammatory prodrug, nabumetone and its principal active metabolite on rat gastric mucosal, aortic and platelet eicosanoid synthesis, in vitro and ex vivo.
    Jeremy JY; Thompson CS; Mikhailidis DP; Dandona P
    Prostaglandins Leukot Essent Fatty Acids; 1990 Nov; 41(3):195-9. PubMed ID: 2281122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nabumetone. Evidence for the lack of enterohepatic circulation of the active metabolite 6-MNA in humans.
    Brett MA; Buscher G; Ellrich E; Greb WH; Kurth HJ; Rülander G; Schmerenbeck B; Haddock RE; Thawley AR
    Drugs; 1990; 40 Suppl 5():67-70. PubMed ID: 2081498
    [No Abstract]   [Full Text] [Related]  

  • 20. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes.
    Turpeinen M; Hofmann U; Klein K; Mürdter T; Schwab M; Zanger UM
    Drug Metab Dispos; 2009 May; 37(5):1017-24. PubMed ID: 19204080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.